Ronit Simantov

14.4k total citations · 4 hit papers
88 papers, 11.2k citations indexed

About

Ronit Simantov is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Oncology. According to data from OpenAlex, Ronit Simantov has authored 88 papers receiving a total of 11.2k indexed citations (citations by other indexed papers that have themselves been cited), including 37 papers in Pulmonary and Respiratory Medicine, 36 papers in Molecular Biology and 26 papers in Oncology. Recurrent topics in Ronit Simantov's work include Renal cell carcinoma treatment (29 papers), Cancer Genomics and Diagnostics (14 papers) and Renal and related cancers (11 papers). Ronit Simantov is often cited by papers focused on Renal cell carcinoma treatment (29 papers), Cancer Genomics and Diagnostics (14 papers) and Renal and related cancers (11 papers). Ronit Simantov collaborates with scholars based in United States, Canada and United Kingdom. Ronit Simantov's co-authors include Brian Schwartz, Martin Gore, Tim Eisen, Walter M. Stadler, Apurva A. Desai, Bernard Escudier, Minghua Shan, Ronald M. Bukowski, Cezary Szczylik and Stéphane Oudard and has published in prestigious journals such as New England Journal of Medicine, Journal of Biological Chemistry and Journal of Clinical Investigation.

In The Last Decade

Ronit Simantov

87 papers receiving 10.9k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma

2007 3.8k citations Tim Eisen, Walter M. Stadler et al. New England Journal of Medicine profile →
Discovery and development of sorafenib: a multikinase inhibitor for treating cancer

2006 1.4k citations Brian Schwartz, Ronit Simantov et al. profile →
Prevalence and Correlates of Accelerated Atherosclerosis in Systemic Lupus Erythematosus

2003 1.1k citations Mary J. Roman, Beth‐Ann Shanker et al. New England Journal of Medicine profile →
Phase II Placebo-Controlled Randomized Discontinuation Trial of Sorafenib in Patients With Metastatic Renal Cell Carcinoma

2006 794 citations Mark J. Ratain, Tim Eisen et al. Journal of Clinical Oncology profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Ronit Simantov	5.5k	4.3k	3.3k	2.6k	1.4k	88	11.2k
Lee J. Helman	7.0k 1.3×	5.0k 1.2×	4.0k 1.2×	2.4k 0.9×	998 0.7×	208	14.3k
Glenn J. Bubley	3.7k 0.7×	7.8k 1.8×	2.7k 0.8×	2.8k 1.0×	860 0.6×	169	12.2k
Stefan Sleijfer	4.2k 0.8×	4.7k 1.1×	7.1k 2.1×	3.5k 1.3×	553 0.4×	379	13.6k
Manisha H. Shah	4.3k 0.8×	3.3k 0.8×	7.7k 2.3×	2.1k 0.8×	630 0.4×	203	18.0k
Patricia Troncoso	3.9k 0.7×	8.0k 1.9×	4.4k 1.3×	2.5k 0.9×	1.8k 1.2×	256	13.8k
François Bertucci	7.5k 1.4×	4.8k 1.1×	8.9k 2.7×	5.4k 2.1×	1.1k 0.7×	515	18.8k
Carsten Stephan	4.9k 0.9×	4.0k 0.9×	1.8k 0.5×	3.3k 1.2×	830 0.6×	248	10.1k
Patrick Pauwels	4.3k 0.8×	3.2k 0.7×	4.2k 1.2×	2.9k 1.1×	601 0.4×	305	10.6k
Filip Jankú	6.7k 1.2×	4.4k 1.0×	6.0k 1.8×	4.3k 1.6×	510 0.4×	430	14.9k
Janice P. Dutcher	6.5k 1.2×	5.8k 1.3×	6.5k 1.9×	3.0k 1.1×	355 0.2×	272	14.7k

Countries citing papers authored by Ronit Simantov

Since Specialization

Citations

This map shows the geographic impact of Ronit Simantov's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ronit Simantov with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ronit Simantov more than expected).

Fields of papers citing papers by Ronit Simantov

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ronit Simantov. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ronit Simantov. The network helps show where Ronit Simantov may publish in the future.

Co-authorship network of co-authors of Ronit Simantov

This figure shows the co-authorship network connecting the top 25 collaborators of Ronit Simantov. A scholar is included among the top collaborators of Ronit Simantov based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ronit Simantov. Ronit Simantov is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Maziarz, Richard T., Usama Gergis, Yan Song, et al.. (2023). Health care costs among patients with hematologic malignancies receiving allogeneic transplants: a US payer perspective. Blood Advances. 8(5). 1200–1208. 1 indexed citations

Lin, Xun, et al.. (2020). The Impact of Age and Gender on Outcomes of Patients With Advanced Renal Cell Carcinoma Treated With Targeted Therapy. Clinical Genitourinary Cancer. 18(5). e598–e609. 9 indexed citations

Lalani, Aly‐Khan A., Wanling Xie, David A. Braun, et al.. (2019). Effect of Antibiotic Use on Outcomes with Systemic Therapies in Metastatic Renal Cell Carcinoma. European Urology Oncology. 3(3). 372–381. 72 indexed citations

Hamieh, Lana, Raphael Brandão Moreira, Xun Lin, et al.. (2018). Impact of Aspirin and Non-Aspirin Nonsteroidal Anti-Inflammatory Drugs on Outcomes in Patients with Metastatic Renal Cell Carcinoma. 2(1). 37–46. 2 indexed citations

Velasco, Guillermo de, Xun Lin, Craig Norton, et al.. (2017). The Clinical Presentation, Survival Outcomes, and Management of Patients With Renal Cell Carcinoma and Cardiac Metastasis Without Inferior Vena Cava Involvement: Results From a Pooled Clinical Trial Database and Systematic Review of Reported Cases. Clinical Genitourinary Cancer. 16(2). e327–e333. 13 indexed citations

Hamieh, Lana, Rana R. McKay, Xun Lin, Ronit Simantov, & Toni K. Choueiri. (2017). Characterization of Patients With Poor-Risk Metastatic Renal-Cell Carcinoma: Results From a Pooled Clinical Trials Database. Clinical Genitourinary Cancer. 16(1). 13–20.e3. 2 indexed citations

Velasco, Guillermo de, et al.. (2017). Comprehensive Analysis of Survival Outcomes in Non–Clear Cell Renal Cell Carcinoma Patients Treated in Clinical Trials. Clinical Genitourinary Cancer. 15(6). 652–660.e1. 33 indexed citations

Sella, Avishay, M. Dror Michaelson, Ewa Matczak, et al.. (2016). Heterogeneity of Patients With Intermediate-Prognosis Metastatic Renal Cell Carcinoma Treated With Sunitinib. Clinical Genitourinary Cancer. 15(2). 291–299.e1. 35 indexed citations

Grünwald, Viktor, Rana R. McKay, Katherine M. Krajewski, et al.. (2015). Depth of Remission is a Prognostic Factor for Survival in Patients with Metastatic Renal Cell Carcinoma. European Urology. 67(5). 952–958. 52 indexed citations

10.

McKay, Rana R., Xun Lin, Laurence Albigès, et al.. (2015). Statins and survival outcomes in patients with metastatic renal cell carcinoma. European Journal of Cancer. 52. 155–162. 40 indexed citations

11.

Puzanov, Igor, Colin R. Lindsay, Laura W. Goff, et al.. (2014). A Phase I Study of Continuous Oral Dosing of OSI-906, a Dual Inhibitor of Insulin-Like Growth Factor-1 and Insulin Receptors, in Patients with Advanced Solid Tumors. Clinical Cancer Research. 21(4). 701–711. 78 indexed citations

12.

Jones, Robin L., Edward S. Kim, Pilar Nava-Parada, et al.. (2014). Phase I Study of Intermittent Oral Dosing of the Insulin-like Growth Factor-1 and Insulin Receptors Inhibitor OSI-906 in Patients With Advanced Solid Tumors. Clinical Cancer Research. 21(4). 693–700. 77 indexed citations

13.

Rose, April A. N., Andrée‐Anne Grosset, Zhifeng Dong, et al.. (2010). Glycoprotein Nonmetastatic B Is an Independent Prognostic Indicator of Recurrence and a Novel Therapeutic Target in Breast Cancer. Clinical Cancer Research. 16(7). 2147–2156. 157 indexed citations

14.

Esmaeli, Bita, et al.. (2009). GPNMB Expression in Uveal Melanomas: A Potential for Targeted Therapy. Investigative Ophthalmology & Visual Science. 50(13). 3385–3385. 1 indexed citations

15.

Ratain, Mark J., Tim Eisen, Walter M. Stadler, et al.. (2006). Phase II Placebo-Controlled Randomized Discontinuation Trial of Sorafenib in Patients With Metastatic Renal Cell Carcinoma. Journal of Clinical Oncology. 24(16). 2505–2512. 794 indexed citations breakdown →

16.

Eisen, Tim, T. Ahmad, Keith T. Flaherty, et al.. (2006). Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis. British Journal of Cancer. 95(5). 581–586. 483 indexed citations

17.

Qi, Ling, Andrew T. Jacovina, Arunkumar B. Deora, et al.. (2004). Annexin II regulates fibrin homeostasis and neoangiogenesis in vivo. Journal of Clinical Investigation. 113(1). 38–48. 318 indexed citations

18.

Roman, Mary J., Beth‐Ann Shanker, Adrienne Davis, et al.. (2003). Prevalence and Correlates of Accelerated Atherosclerosis in Systemic Lupus Erythematosus. New England Journal of Medicine. 349(25). 2399–2406. 1053 indexed citations breakdown →

19.

Simantov, Ronit, et al.. (2001). Histidine-rich glycoprotein inhibits the antiangiogenic effect of thrombospondin-1. Journal of Clinical Investigation. 107(1). 45–52. 93 indexed citations

20.

Sobel, Rachel E., S K Lo, Ronit Simantov, et al.. (1997). Anticardiolipin IgG subclasses association of IgG2 with arterial and/or venous thrombosis. Arthritis & Rheumatism. 40(11). 1998–2006. 63 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact